FigureAsia 35 Under 35 · Healthcare
Serene Cai Huiting
Age 34 · Home-based care and telehealth · Singapore
Physician-founder whose platform reports more than 300,000 home visits, over 500 licensed clinicians and partnerships with more than 20 hospitals across two countries.
- Approximate age at 31 December 2025
- 34
- Field
- Healthcare
- Country or region
- Singapore
- FigureAsia U35 Assessment
- 88.0 / 100
Profile
Career and documented record
Serene Cai has helped build a care model around a simple observation: many patients need clinical attention but do not need to begin in a hospital. By 2025–2026, the service she cofounded reported more than 300,000 home visits, over 500 licensed clinicians and more than 20 hospital partners across Singapore and Malaysia. Cai also contributed to Singapore's 2025 policy discussion on how telehealth should be governed and integrated.
The operational contribution is the connective layer — clinician dispatch, remote assessment, diagnostics, medication and escalation — rather than a video call in isolation. Cai's operating role gives her direct responsibility for how that pathway connects logistics, continuity and hospital standards; clinical decisions remain with licensed professionals. The model has particular relevance to older adults, post-discharge patients and families for whom travel is itself a barrier.
Scale figures are company-reported and do not establish that every home visit prevented an admission or improved an outcome. The platform's quality must be judged by clinical governance, escalation and comparative evidence as it grows. Cai's inclusion recognizes the creation of a substantial Southeast Asian home-care network and her role in shaping the policy environment around it.
FigureAsia selection
Why Serene Cai Huiting is on the list
FigureAsia selected Cai because she has combined delivery at scale with participation in public policy. Her work treats the home as part of the health system and has built links to hospitals rather than positioning telehealth as a substitute for them. The score is moderated by the provenance of operating metrics and limited published outcome comparisons; it rewards infrastructure, reach and operating agency.
Verified work
The 2025–26 record
Principal milestone
More than 300,000 home visits reported
Evidence record
More than 500 licensed clinicians
Scale or implementation
More than 20 hospital partners across two countries
Field context
The work in its field
Within home-based care and telehealth, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.
FigureAsia U35 Assessment
Assessment breakdown
88.0out of 100
Substantive 2025–2026 contribution
18 / 20
The score reflects completed 2025–26 work in home-based care and telehealth, assessed at the documented maturity of deployed home-care and telehealth network.
Verified impact
12 / 15
Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.
Originality and distinction
8 / 10
The work creates or materially advances a distinctive capability within home-based care and telehealth rather than relying on title or institutional association.
Field and industry influence
9 / 10
The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.
Individual agency
10 / 10
Named authorship and the documented role of Cofounder establish individual responsibility while preserving credit for collaborators.
Durability and trajectory
4.5 / 5
The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.
Asian significance and global relevance
5 / 5
The Asian connection is material to the person's identity, operating base or populations served: Singaporean physician-founder.
Clinical and scientific validity
4.9 / 7
Clinical and scientific validity is calibrated to deployed home-care and telehealth network, with the profile retaining the evidence boundary attached to the result.
Safety, quality and responsible governance
5.6 / 7
Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.
Translation and care-pathway fit
6 / 6
The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.
Access, equity and resource stewardship
5 / 5
Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.